ProstaCaid

a 33 ingredient polybotanical dietary supplement with antineoplastic activity; complete composition given in first source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	Eliaz, Isaac: 2 articles (03/2013 - 05/2012)
2.	Jiang, Jiahua: 2 articles (03/2013 - 05/2012)
3.	Sliva, Daniel: 2 articles (03/2013 - 05/2012)
4.	Loganathan, Jagadish: 1 article (05/2012)
5.	Sandusky, George E: 1 article (05/2012)
6.	Terry, Colin: 1 article (05/2012)
7.	Katz, Aaron E: 1 article (06/2010)
8.	Yan, Jun: 1 article (06/2010)

1.	Prostatic Neoplasms (Prostate Cancer) 05/01/2012 - "Our study demonstrates that the concentrations of the dietary supplement ProstaCaid tested did not show signs of toxicity, and its oral application has significant anticancer activity in vivo and can be considered as an alternative treatment for prostate cancer patients." 05/01/2012 - "We have recently demonstrated that the dietary supplement ProstaCaid (PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro. " 06/01/2010 - "In summary, these findings strongly suggest that ProstaCaid may be a potential chemopreventive and therapeutic agent for both AD and, more importantly, AI prostate cancer." 06/01/2010 - "Consistently, long-term treatment with ProstaCaid also reduced colony formation capacities of prostate cancer cells. " 06/01/2010 - "ProstaCaid shows growth inhibitory effects on both human and mouse AD prostate cancer cells (LNCaP and CASP 2.1) and AI prostate cancer cells (PC3 and CASP 1.1) in a dose-/time-dependent manner. "
2.	Neoplasms (Cancer) 05/01/2012 - "ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer."